SL Bio Lists on Nasdaq Following Merger with Horizon Space

TAIPEI, Taiwan, June 12, 2026 - SL Bio Ltd. has successfully finalized its business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT). The post-combination entity, now named SL Science Holding Limited, is set to begin trading on the Nasdaq Global Market under the ticker symbol SLBT beginning June 15, 2026.

Transaction Details

• The transaction represents an implied equity valuation of approximately $5.568 billion for SL Bio.
• The merger was supported by a concurrent closing of a $7.8 million PIPE financing, providing critical capital for operational growth.
• SL Bio and Horizon Space are now wholly owned subsidiaries of the newly formed Cayman Islands holding company, SL Science.

Strategic Objectives

The newly capitalized entity intends to utilize the proceeds to accelerate the development of its proprietary Gamma delta T (GDT) cell-based therapy platforms. These technologies are focused on addressing solid tumor indications, such as pancreatic and brain cancers. By transitioning from traditional autologous therapies to a more scalable, off-the-shelf industrial model, the company aims to reduce manufacturing complexity and costs while enhancing accessibility to clinical treatments.

Executive Leadership and Governance

To support its mission as a U.S.-listed public entity, the company has established a robust governance structure. William Wang serves as Chief Executive Officer and Chairman, leading a management team that includes Chief Financial Officer Ray Leung and Chief Technology Officer Ethan Shen. The Board of Directors has been bolstered by the addition of five independent directors, ensuring oversight in accounting, financial reporting, and regulatory compliance.